Wildfire pollution may lower survival of lung cancer patients

City of Hope brings evidence-based approaches to integrative oncology

The landscape of cancer care is evolving rapidly, with growing recognition that optimal patient outcomes require a whole-person care approach that goes beyond cytotoxic and targeted therapies.

Six researchers awarded $5.3M for pancreatic cancer research by Stephenson Global

The Stephenson Global Pancreatic Cancer Research Institute and its partner, City of Hope, announced the six inaugural recipients of the Stephenson Scholar Grants, awarding $5.25 million to support high-impact research aimed at transforming the understanding, early detection, and treatment of pancreatic cancer (The Cancer Letter, Sept. 17, 2024).

July 25, 2025

Vol.51 No.29

In Brief

Dispatch Bio aims to deliver universal treatment across solid tumors with novel immunotherapy approach

Dispatch Bio, a company aiming to engineer a universal immunotherapy treatment across solid tumors, announced its official launch.

July 25, 2025

Vol.51 No.29

In Brief

Geraldine O’Sullivan Coyne to lead early-stage clinical trials at Northwell’s START Center for Cancer Research

Geraldine O’Sullivan Coyne was appointed system head of Northwell and principal investigator for the START Center for Cancer Research, a newly established unit at the health system aimed at bringing innovative early stage clinical trials to patients in a community-based cancer center.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Tumor-infiltrating clonal hematopoiesis is prevalent across solid tumors with the highest incidence in non-small cell lung cancer and results in a higher rate of mortality, according to a study by Caris Life Sciences that independently validates recent findings on TI-CH.

July 25, 2025

Vol.51 No.29

Wildfire pollution may lower survival of lung cancer patients

YOU MAY BE INTERESTED IN

City of Hope brings evidence-based approaches to integrative oncology

Six researchers awarded $5.3M for pancreatic cancer research by Stephenson Global

Dispatch Bio aims to deliver universal treatment across solid tumors with novel immunotherapy approach

Geraldine O’Sullivan Coyne to lead early-stage clinical trials at Northwell’s START Center for Cancer Research

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Renew today!

Subscriber content

Never miss an issue!

Login